People
The biopharma industry strives to bring in more voices at the corporate level and clinical trials. But, there is still a long way to go, especially with companies helmed by minorities.
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The additional 100 people will be placed in Seattle, San Francisco, and Cambridge, Mass. by the end of the year.
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
The tiny heart organoids, dubbed “cardioids,” even begun beating similarly as real miniature hearts, making them the most realistic heart organoids developed to date.
Maria Fardis, who has been with the company since 2016, stepped down as CEO following FDA’s delay on its Biologics License Application.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Forbes highlights its “30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.
PRESS RELEASES